Ones To Watch News
Refine Search
Biotechnology
One of the world’s leading specialists in mRNA therapeutics has partnered with California’s CytomX Therapeutics to create novel cancer meds. 6 January 2023
Biotechnology
US immunology specialist Acelyrin has acquired ValenzaBio, a privately-held company developing therapies for autoimmune and inflammatory diseases, in an all-stock transaction. 5 January 2023
Biotechnology
US precision medicines firm Frontier Medicines today announced the second and third programs under the company's global partnership with AbbVie have advanced into lead generation. 5 January 2023
Biotechnology
An eye-catching start to life has put Belharra Therapeutics firmly on the biotech map. 5 January 2023
Biotechnology
Privately held Danish biotechnology company MinervaX has appointed Lidia Oostvogels as chief medical officer, bringing a wealth of experience in vaccine development with more than 25 years’ experience in clinical development. 5 January 2023
Biotechnology
US biotech star-up Capsida Biotherapeutics has entered a multi-year strategic collaboration with pharma major Eli Lilly’s subsidiary Prevail to develop transformative genetic medicines for serious diseases. 5 January 2023
Biotechnology
It has been a long road for Geron’s telomerase blocker, but the company is now finally planning a commercial launch for imetelstat in 2024. 5 January 2023
Biotechnology
A report from industry commentator GlobalData highlights the potential for cell therapies to transform the treatment of multiple sclerosis (MS). 5 January 2023
Generics
Finnish drugmaker Orion Corporation says it has signed a long-term license agreement with US drugmaker Amneal Pharmaceuticals, to commercialize Amneal’s generic products in Orion territories. 5 January 2023
Pharmaceutical
UK-based ADVANZ PHARMA has acquired exclusive rights to register and commercialize AT-007, a Phase III development compound for the treatment of several rare neurological diseases, including galactosemia and SORD deficiency, in the European Economic Area, the UK, and Switzerland. 4 January 2023
Pharmaceutical
Canadian firm Aurinia Pharmaceuticals and India’s Sun Pharmaceutical have moved quickly to settle a patent dispute in the US market. 4 January 2023
Biotechnology
Switzerland-based biotech ADC Therapeutics today announced the appointment of Dr Mohamed Zaki as chief medical officer, bringing over 20 years of experience in hematology and oncology drug development to his role. 4 January 2023
Biotechnology
USA-based tumor drug resistance specialist Deciphera Pharmaceuticals saw its shares close down 2.7% at $15.94 yesterday, after it announced findings of a planned exploratory analysis of data from the INTRIGUE Phase III clinical study of Qinlock (ripretinib) using circulating tumor DNA (ctDNA) from a subgroup of patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib who harbor mutations in KIT exon 11 and 17/18 only. 4 January 2023
Biotechnology
Swedish company Alligator Bioscience yesterday announced an expansion to its research collaboration and license agreement with Finland-based Orion Corporation, to discover and develop together new bispecific antibody cancer therapeutics. 3 January 2023
Generics
The supervisory board of German drugmaker STADA Arzneimittel has appointed Boris Döbler as group chief financial officer (CFO) with effect from January 1, 2023. 3 January 2023
Biotechnology
US retinal diseases focussed start-up Opus Genetics has acquired the rights to two pre-clinical-stage AAV-based gene therapy product candidates for inherited retinal diseases (IRDs) from Iveric Bio. 29 December 2022
Biotechnology
Belgium’s privately-held biotech Novadip Biosciences today announced the appointment of Judy Ashworth as chief medical office (CMO). 28 December 2022
Biotechnology
Shares of Jounce Therapeutics were trading up a massive 72% at $1.27 pre-market, on the news that biotech major Gilead Sciences is amending an existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to buy out remaining contingent payments potentially due under the license agreement executed in August 2020. 28 December 2022
Biotechnology
Germany’s Merck KGaA has embarked on a new research collaboration with Mersana Therapeutics (Nasdaq: MRSN), including terms for a commercial license. 23 December 2022
Pharmaceutical
Respiratory disease specialist Verona Pharma has seen its shares jump from around $13 to $18 following positive results from the Phase III ENHANCE-1 trial. 21 December 2022
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze